Clinical trials: Partial Response
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06238648
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Academic and Community Cancer Research United
Nasopharyngeal Carcinoma, De-escalation Therapy
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
This prospective trial aims to enroll patients with stage III-IVA (AJCC 8th,) locoregionally advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06675214
- Testing
- Full course of PD-1/PD-L1 blockades, Cisplatin-based induction chemotherapy, Standard-dose IMRT
- Where
- China
- Volunteers
- 586 people
- Sponsor
- Sun Yat-sen University
Major Depressive Disorder (MDD)
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive…
- Trial name
- NCT01187407
- Testing
- LY2216684, SSRI
- Where
- 54 sites in United States, Croatia and 5 more
- Volunteers
- 1,480 people
- Sponsor
- Eli Lilly and Company
Focal Segmental Glomerulosclerosis
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
- Trial name
- AURONA™ (NCT03598036)
- Testing
- Voclosporin
- Where
- 23 sites in United States, Dominican Republic
- Volunteers
- 5 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Autoimmune Hepatitis
Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy
Rationale: The combination of azathioprine and prednisone is the first-line treatment for autoimmune hepatitis (AIH), a chronic inflammatory disease of the liver.
- Trial name
- TAILOR (NCT05221411)
- Testing
- Mycophenolate Mofetil, Tacrolimus
- Where
- 6 sites in Netherlands
- Volunteers
- 86 people
- Sponsor
- Leiden University Medical Center
Breast Cancer, Ductal Carcinoma in Situ
Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer
In the management of early breast cancer patients, postoperative radiotherapy following breast-conserving surgery has been established as the standard treatment.
- Conditions
- Breast Cancer, Ductal Carcinoma in Situ, Invasive Breast Cancer
- Trial name
- NCT06677944
- Testing
- Preoperative PBI
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Yonsei University
Major Depressive Disorder
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode.
- Trial name
- NCT01684163
- Testing
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg
- Where
- 26 sites in United States
- Volunteers
- 369 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Depression
Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)
The primary aims of this study are to: 1. Assess the efficacy of aripiprazole augmentation for the acute and continuation treatment of TRLLD.
- Trial name
- IRL GREY (NCT00892047)
- Testing
- venlafaxine XR plus aripiprazole
- Where
- 3 sites in United States, Canada
- Volunteers
- 468 people
- Sponsor
- University of Pittsburgh
Invasive Ductal Breast Cancer, Tubular Breast Cancer
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
This trial will compare the administration of 2 cycles of paclitaxel and cisplatin (DP) versus 4 cycles of CEF as adjuvant chemotherapy for the patients with locally advanced breast cancer and who were pathological partial…
- Conditions
- Invasive Ductal Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, Inflammatory Breast Cancer
- Trial name
- NCT02879513
- Testing
- Paclitaxel, Cisplatin, Epirubicin
- Where
- China
- Volunteers
- 290 people
- Sponsor
- RenJi Hospital
Acute Kidney Injury, Sepsis
Can Urinary Partial Oxygen Pressure be an Indicator of Acute Kidney Injury in Patients With Sepsis?
The ability of bladder urinary partial pressure, measured as a reflection of renal medullary oxygen tension, which is an indicator of the development of acute kidney injury (AKI), to predict the development of AKI at an early…
- Trial name
- NCT06124105
- Testing
- arterial blood gases
- Volunteers
- 68 people
- Sponsor
- Inonu University
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
This phase I trial studies the safety of SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim in treating patients with newly diagnosed multiple myeloma who are receiving lenalidomide…
- Trial name
- NCT02334865
- Testing
- Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Breast Carcinoma, Ipsilateral Recurrence
Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial
Over the past decades, interest in second breast-conserving therapy (BCT) has increased due to, among others, advancements in radiotherapy techniques.
- Trial name
- REPEAT (NCT06640881)
- Testing
- ablative single-dose PBI
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Amsterdam UMC, location VUmc
Fabry Disease
Dosing Study of Replagal in Patients With Fabry Disease
This study will determine the safety and effectiveness of increasing Replagal infusions in certain patients with Fabry disease. Replagal is a genetically engineered form of Alpha-galactosidase A, an enzyme that normally breaks…
- Trial name
- NCT00068107
- Testing
- Replagal
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Psoriasis
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis.
- Trial name
- NCT00638469
- Testing
- UVB-311nm, No treatment
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Graz
Chronic Hepatitis B
Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
The objectives are to demonstrate that entecavir has antiviral activity undetectable HBV DNA measured, the Roche AmplicorTM PCR at Week 48, and to assess the safety and the pharmacokinetic of entecavir in Japanese patients with…
- Trial name
- NCT01037166
- Testing
- Entecavir
- Where
- 16 sites in Japan
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Depression
Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression
The purpose of the study is to determine whether changing sleep patterns improves response to an antidepressant medication.
- Trial name
- NCT01545843
- Testing
- Sleep scheduling, Fluoxetine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan
Benign Epilepsy With Centrotemporal Spikes
18F-FDG PET Imaging Analysis of Antiepileptic Drug Response in BECTS
This original article is a novel investigation on the metabolic characteristics of different patterns of antiepileptic drug (AED) responses in benign epilepsy with centrotemporal spikes (BECTS) patients using 18F-FDG PET imaging.
- Trial name
- NCT04357236
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Type 1 Diabetes
A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D)
The purpose of this research study is to investigate the effects of a combination of weekly distribution of healthy foods and intensive nutrition counseling as complementary therapies to the standard insulin therapy in children…
- Trial name
- NUTRI-Beta (NCT06640478)
- Testing
- NUTRI-Beta Counseling, Standard dietary counseling, Free weekly produce foods
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center